株探米国株
英語
エドガーで原本を確認する
6-K 1 rdy0883_6k.htm FORM 6-K
 


SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

April, 2026

 

Commission File Number 1-15182

 

DR. REDDY’S LABORATORIES LIMITED

(Translation of registrant’s name into English)

 

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Telangana 500 034, India

+91-40-49002900

 

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F  x                                       Form 40-F  ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ______

 

Note:  Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ______

 

Note:  Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

 

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes  ¨                                       No  x

 

If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.

 

 

 

EXHIBITS

 

Exhibit

Number

  

Description of Exhibits

 

 

 

99.1


Intimation dated April 07, 2026

 

2

 

SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

DR. REDDY’S LABORATORIES LIMITED

(Registrant)

 

 

Date: April 07, 2026

By:

/s/ K Randhir Singh

 

 

Name:

K Randhir Singh

 

 

Title:

Company Secretary

 

3
EX-99.1 2 rdy0883_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

Dr. Reddy's Laboratories Ltd.

8-2-337, Road No. 3, Banjara Hills

Hyderabad – 500 034, Telangana, India

CIN: L85195TG1984PLC004507

Tel:       + 91 40 4900 2900

Fax:     + 91 40 4900 2999

Email: mail@drreddys.com

Web:   www.drreddys.com

 

April 7, 2026

 

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)

BSE Limited (Scrip Code: 500124) 

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd (Stock Code: DRREDDY)

 

Dear Sir/Madam, 

 

Sub:

Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Sale of wholly owned subsidiary of the Company.

 

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), as amended, we wish to inform that Dr. Reddy’s Laboratories Limited (“The Company”), has today, i.e. April 7, 2026, entered into an agreement for sale of its entire shareholding in its wholly owned subsidiary, Svaas Wellness Limited.

 

Consequent to the completion of the transaction, Svaas Wellness Limited will cease to be a wholly owned subsidiary of the Company.

 

The requisite details as prescribed under Regulation 30 of the SEBI Listing Regulations, read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is enclosed herewith as Annexure. 

 

This is for your information and record. 

 

Thanking you. 

 

Yours faithfully, 

For Dr. Reddy’s Laboratories Limited


K Randhir Singh 

Company Secretary, Compliance Officer, and Head-CSR Disclosure under Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

 

Encl: as above 

 

 

Dr. Reddy's Laboratories Ltd.

8-2-337, Road No. 3, Banjara Hills

Hyderabad – 500 034, Telangana, India

CIN: L85195TG1984PLC004507

Tel:       + 91 40 4900 2900

Fax:     + 91 40 4900 2999

Email: mail@drreddys.com

Web:   www.drreddys.com

 

Annexure


 

Sl.

No

Particulars

Description

1

The amount and percentage of the turnover or revenue or income and net worth contributed by such subsidiary company of the listed entity during the last financial year

The turnover of Svaas Wellness Limited as per FY 2025 audited financials was Rs. 28.5 Crore (100% turnover was from Dr. Reddy’s Laboratories Limited), constituting ~0.09% of the consolidated turnover.

 

2

Date on which the agreement for sale has been entered into

April 7, 2026

3

The expected date of completion of sale/disposal

April 7, 2026

4

Consideration received from such sale/disposal

INR 2.23 Cr

5

Brief details of buyers and whether any of the buyers belong to the promoter/promoter group/group companies. If yes, details thereof

Enspirit Technology Services Private Limited, having its registered office at 3-6-465, Flat 206, Legend Siddhi, Street 5, Himayathnagar, Hyderabad - 500029, Telangana, India.

 

The buyer does not belong to Promoter / Promoter group/ group of Companies of the Company.

 

6

Whether the transaction would fall within related party transactions? If yes, whether the same is done at “arm’s length”

The transaction does not constitute a related party transaction. Enspirit Technology Services Private Limited is not a related party of the Company or any of its subsidiaries.

 

7

Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations.

Not applicable

8

Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale.

Not applicable